Trilogy Capital Inc. Makes New Investment in MetLife, Inc. $MET

Key Points

• Trilogy Capital acquired a new position of 38,434 shares in MetLife in Q4, valued at about $3.03 million, and institutional investors now own roughly 94.99% of the stock as several other funds also added or increased positions.
• Analysts have a consensus rating of "Moderate Buy" with a consensus price target of $93.67; UBS raised its target to $102 (≈36% upside) while Morgan Stanley and Barclays trimmed their targets modestly, signaling generally positive but mixed sentiment.
• MetLife beat quarterly EPS expectations ($2.49 vs. $2.34) and reported revenue up 27.6% YoY to $52.44 billion; the stock trades around $74.66 (market cap ≈ $48.7B) and upcoming Q1 results (May 6) are a near‑term catalyst.

Trilogy Capital Inc. acquired a new position in MetLife, Inc. (NYSE:MET - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 38,434 shares of the financial services provider's stock, valued at approximately $3,034,000.

Several other hedge funds have also recently modified their holdings of MET. Brighton Jones LLC raised its position in shares of MetLife by 9.0% during the 4th quarter. Brighton Jones LLC now owns 4,240 shares of the financial services provider's stock worth $347,000 after purchasing an additional 351 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of MetLife during the 1st quarter worth about $307,000. Empowered Funds LLC raised its position in shares of MetLife by 187.6% during the 1st quarter. Empowered Funds LLC now owns 33,378 shares of the financial services provider's stock worth $2,680,000 after purchasing an additional 21,771 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of MetLife during the 2nd quarter worth about $404,000. Finally, Brown Advisory Inc. raised its position in shares of MetLife by 16.4% during the 2nd quarter. Brown Advisory Inc. now owns 19,021 shares of the financial services provider's stock worth $1,530,000 after purchasing an additional 2,686 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on MET shares. Morgan Stanley reduced their price target on shares of MetLife from $101.00 to $93.00 and set an "overweight" rating for the company in a research report on Tuesday, March 3rd. Barclays reduced their price target on shares of MetLife from $92.00 to $89.00 and set an "overweight" rating for the company in a research report on Wednesday. UBS Group upped their price target on shares of MetLife from $98.00 to $102.00 and gave the stock a "buy" rating in a research report on Thursday. Mizuho set a $100.00 price target on shares of MetLife in a research report on Thursday, February 12th. Finally, Evercore set a $95.00 price objective on shares of MetLife in a research note on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, MetLife currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.67.

MetLife Stock Up 0.4%

Shares of NYSE MET opened at $74.66 on Friday. MetLife, Inc. has a 12-month low of $67.33 and a 12-month high of $83.85. The stock has a market cap of $48.68 billion, a PE ratio of 15.88, a P/E/G ratio of 0.67 and a beta of 0.74. The company has a current ratio of 0.20, a quick ratio of 0.20 and a debt-to-equity ratio of 0.52. The company has a 50-day moving average of $73.29 and a 200 day moving average of $77.04.

MetLife (NYSE:MET - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The financial services provider reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.34 by $0.15. MetLife had a net margin of 4.38% and a return on equity of 21.81%. The company had revenue of $52.44 billion during the quarter, compared to analysts' expectations of $31.43 billion. During the same quarter in the prior year, the company earned $2.08 EPS. MetLife's revenue was up 27.6% compared to the same quarter last year. As a group, sell-side analysts predict that MetLife, Inc. will post 9.65 EPS for the current fiscal year.

Trending Headlines about MetLife

Here are the key news stories impacting MetLife this week:

• Positive Sentiment: UBS raised its price target on MET to $102 and upgraded the stock to a "buy" (implying ~36% upside from current levels), signaling stronger analyst conviction that can attract buyers. Article Title
• Positive Sentiment: MetLife set its Q1 2026 earnings release for May 6 (call on May 7) and analysts expect double‑digit bottom‑line growth — a near‑term catalyst where an earnings beat could extend the rally. Article Title Article Title
• Neutral Sentiment: Barclays trimmed its price target from $92 to $89 but kept an "overweight" rating — a modestly less bullish view that nonetheless still supports upside, making this a mixed signal for investors. Article Title
• Neutral Sentiment: MetLife Foundation awarded grants to 26 non‑profits across Asia as part of global community programs — positive for ESG/brand but unlikely to move near‑term financials. Article Title
• Neutral Sentiment: World Cup events tied to MetLife Stadium (fan festivals, and reports that Penn Station may partially close during matches) raise short‑term operational/PR headlines tied to the MetLife name but have limited direct impact on corporate earnings. Article Title Article Title

MetLife Company Profile

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.